Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00433147 · ClinicalTrials.gov registry record · Phase 2

A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy

A Phase 2 study of Gaucher Disease and Gaucher Disease, Type 1, sponsored by Amicus Therapeutics.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target
10
Study locations

NCT00433147 is a Phase 2 study of Gaucher Disease and Gaucher Disease, Type 1 that has completed, run by Amicus Therapeutics. The registered enrollment target is 30 participants, below the 1,056-participant average among 13 other Gaucher Disease trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00433147, a Phase 2 study of Gaucher Disease and Gaucher Disease, Type 1, has completed, sponsored by Amicus Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target
10
Study locations

Study Summary

This study was conducted to test the safety and tolerability of afegostat tartrate in participants with type 1 Gaucher disease already receiving enzyme replacement therapy.

Interventions

  • DRUG Afegostat tartrate

Study Locations (10)

Pennsylvania

  • - Philadelphia
  • - Pittsburgh

California

  • - San Francisco

Florida

  • - Coral Springs

Georgia

  • - Decatur

Iowa

  • - Iowa City

New York

  • - New York

Ohio

  • - Cincinnati

Oregon

  • - Portland

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2007-03-23
Est. Completion 2008-02-19
Phase Phase 2

Sponsor

Amicus Therapeutics

34 total trials

What the Registry Record Tells You About NCT00433147

The ClinicalTrials.gov registry entry for NCT00433147 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,056-participant average among 13 other Gaucher Disease trials with a reported enrollment target (97% lower). The listed sponsor is Amicus Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Gaucher Disease appearing as the primary indexed condition, and to 1 intervention - of which Afegostat tartrate is the first listed.

NCT00433147 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Pennsylvania, California, Florida.

Frequently Asked Questions

What is clinical trial NCT00433147 about?

NCT00433147 is a clinical study titled "A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy". This study was conducted to test the safety and tolerability of afegostat tartrate in participants with type 1 Gaucher disease already receiving enzyme replacement therapy.

What is the current status of trial NCT00433147?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2007-03-23. Estimated completion is 2008-02-19.

What conditions does trial NCT00433147 study?

This clinical trial studies the following conditions: Gaucher Disease, Gaucher Disease, Type 1, Type 1 Gaucher Disease.

What interventions are being tested in trial NCT00433147?

The interventions under investigation include: Afegostat tartrate (DRUG).

Who is sponsoring clinical trial NCT00433147?

This trial is sponsored by Amicus Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00433147 being conducted?

This trial has 10 study locations across California, Florida, Georgia, Iowa, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gaucher Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.